Sign Out
Pregnancy: YSP BRIMOLOL EYE DROP should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the foetus.
Brimonidine tartrate: No adequate clinical data on exposed pregnancies are available.
Timolol: There is risk for intrauterine growth retardation when beta-blockers are administered by the oral route.
In addition, signs and symptoms of beta-blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in the neonate when betablockers have been administered until delivery. If the YSP BRIMOLOL EYE DROP is administered until delivery, the neonate should be carefully monitored during the first days of life. YSP BRIMOLOL EYE DROP should not be used during pregnancy unless clearly necessary.
Lactation: Timolol is excreted in human milk. YSP BRIMOLOL EYE DROP should not be used by women breastfeeding infants.
